Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors

Felix Scheuplein(Blueprint Medicines (United States)), James R. Bischoff(Spanish National Cancer Research Centre)
Frontiers in Immunology
October 21, 2024
Cited by 4


Related Papers